Találati lista | Tudóstér

001-es BibID:	BIBFORM103510
035-os BibID:	(Wos)000841921200031 (Scopus)85136851907
Első szerző:	Mearin, Maria Luisa
Cím:	ESPGHAN Position Paper on Management and Follow-up of Children and Adolescents With Celiac Disease / Mearin Maria Luisa, Agardh Daniel, Antunes Henedina, Al-toma Abdul, Auricchio Renata, Castillejo Gemma, Catassi Carlo, Ciacci Carolina, Discepolo Valentina, Dolinsek Jernej, Donat Ester, Gillett Peter, Guandalini Steffano, Husby Steffen, Koletzko Sibylle, Koltai Tunde, Korponay-Szabó Ilma Rita, Kurppa Kalle, Lionetti Elena, Marild Karl, Martinez Ojinaga Eva, Meijer Caroline, Monachesi Chiara, Polanco Isabel, Popp Alina, Roca Maria, Rodriguez-Herrera Alfonso, Shamir Raanan, Størdal Ketil, Troncone Riccardo, Valitutti Francesco, Vreugdenhil Anita, Wessels Margreet, Whiting Penny, ESPGHAN Special Interest Group on Celiac Disease
Dátum:	2022
ISSN:	0277-2116
Megjegyzések:	Objectives: To gather the current evidence and to offer recommendations for follow-up and management. Methods: The Special Interest Group on Celiac Diseases of the European Society of Paediatric Gastroenterology Hepatology and Nutrition formulated ten questions considered to be essential for follow-up care. A literature search (January 2010-March 2020) was performed in PubMed or Medline. Relevant publications were identified and potentially eligible studies were assessed. Statements and recommendations were developed and discussed by all coauthors. Recommendations were voted upon: joint agreement was set as at least 85%. Results: Publications (n = 2775) were identified and 164 were included. Using evidence or expert opinion, 37 recommendations were formulated on: The need to perform follow-up, its frequency and what should be assessed, how to assess adherence to the gluten-free diet, when to expect catch-up growth, how to treat anemia, how to approach persistent high serum levels of antibodies against tissue-transglutaminase, the indication to perform biopsies, assessment of quality of life, management of children with unclear diagnosis for which a gluten-challenge is indicated, children with associated type 1 diabetes or IgA deficiency, cases of potential celiac disease, which professionals should perform follow-up, how to improve the communication to patients and their parents/caregivers and transition from pediatric to adult health care. Conclusions: We offer recommendations to improve follow-up of children and adolescents with celiac disease and highlight gaps that should be investigated to further improve management.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Journal Of Pediatric Gastroenterology And Nutrition. - 75 : 3 (2022), p. 369-386. -
További szerzők:	Agardh, Daniel Antunes, Henedina Al-toma, Abdul Auricchio, Renata Castillejo, Gemma (gyermekgyógyász, gasztroenterológus) Catassi, Carlo Ciacci, Carolina Discepolo, Valentina Dolinśek, Jernej Donat, Ester Gillett, Peter Guandalini, Steffano Husby, Steffen Koletzko, Sibylle Koltai Tünde Korponay-Szabó Ilma (1959-) (gyermekgyógyász) Kurppa, Kalle Lionetti, Elena Marild, Karl Martinez Ojinaga, Eva Meijer, Caroline R. Monachesi, Chiara Polanco, Isabel Popp, Alina Roca, María Rodriguez-Herrera, Alfonso Shamir, Raanan (gyermekgyógyász) Størdal, Ketil Troncone, Riccardo Valitutti, Francesco Vreugdenhil, Anita C. E. Wessels, Margreet Whiting, Penny ESPGHAN Special Interest Group on Celiac Disease
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM048562
Első szerző:	Tack, Greetje J.
Cím:	Consumption of gluten with gluten-degrading enzyme by celiac patients : a pilot-study / Greetje J. Tack, Jolanda M. W. van de Water, Maaike J. Bruins, Engelina M. C. Kooy-Winkelaar, Jeroen van Bergen, Petra Bonnet, Anita C. E. Vreugdenhil, Ilma Korponay-Szabo, Luppo Edens, B. Mary E. von Blomberg, Marco W. J. Schreurs, Chris J. Mulder, Frits Koning
Dátum:	2013
ISSN:	1007-9327
Megjegyzések:	AIM:To assesses the safety and efficacy of Aspergillus niger prolyl endoprotease (AN-PEP) to mitigate the immunogenic effects of gluten in celiac patients.METHODS:Patients with initial diagnosis of celiac disease as confirmed by positive serology with subtotal or total villous atrophy on duodenal biopsies who adhere to a strict gluten-free diet (GFD) resulting in normalised antibodies and mucosal healing classified as Marsh 0 or I were included. In a randomised double-blind placebo-controlled pilot study, patients consumed toast (approximately 7 g/d gluten) with AN-PEP for 2 wk (safety phase). After a 2-wk washout period with adherence of the usual GFD, 14 patients were randomised to gluten intake with either AN-PEP or placebo for 2 wk (efficacy phase). Measurements at baseline included complaints, quality-of-life, serum antibodies, immunophenotyping of T-cells and duodenal mucosa immunohistology. Furthermore, serum and quality of life questionnaires were collected during and after the safety, washout and efficacy phase. Duodenal biopsies were collected after the safety phase and after the efficacy phase. A change in histological evaluation according to the modified Marsh classification was the primary endpoint.RESULTS:In total, 16 adults were enrolled in the study. No serious adverse events occurred during the trial and no patients withdrew during the trial. The mean score for the gastrointestinal subcategory of the celiac disease quality (CDQ) was relatively high throughout the study, indicating that AN-PEP was well tolerated. In the efficacy phase, the CDQ scores of patients consuming gluten with placebo or gluten with AN-PEP did not significantly deteriorate and moreover no differences between the groups were observed. During the efficacy phase, neither the placebo nor the AN-PEP group developed significant antibody titers. The IgA-EM concentrations remained negative in both groups. Two patients were excluded from entering the efficacy phase as their mucosa showed an increase of two Marsh steps after the safety phase, yet with undetectable serum antibodies, while 14 patients were considered histologically stable on gluten with AN-PEP. Also after the efficacy phase, no significant deterioration was observed regarding immunohistological and flow cytometric evaluation in the group consuming placebo compared to the group receiving AN-PEP. Furthermore, IgA-tTG deposit staining increased after 2 wk of gluten compared to baseline in four out of seven patients on placebo. In the seven patients receiving AN-PEP, one patient showed increased and one showed decreased IgA-tTG deposits.CONCLUSION:AN-PEP appears to be well tolerated. However, the primary endpoint was not met due to lack of clinical deterioration upon placebo, impeding an effect of AN-PEP.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Adverse events Aspergillus niger prolyl endoprotease Celiac disease Enzyme IgA-tTG intestinal deposits Prolyl endoprotease
Megjelenés:	World Journal of Gastroenterology 19 : 35 (2013), p. 5837-5847. -
További szerzők:	Water, Jolanda M. W. van de Bruins, Maaike J. Kooy-Winkelaar, Engelina M. C. Bergen, Jeroen van Bonnet, Petra Vreugdenhil, Anita C. E. Korponay-Szabó Ilma (1959-) (gyermekgyógyász) Edens, Luppo Blomberg, B. Mary E. von Schreurs, Marco W. J. Mulder, Chris J. Koning, Frits
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: